Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9961 - 9968 of 12089 results
Staffing Companies Hit with Class Action Alleging Violation of Fair Credit Reporting Act
December 15, 2014| Blog| Viewpoint
For the First Time PTAB Upholds Validity of Pharma Patents
December 15, 2014| Blog| Viewpoint
Vermont Doubles Down: Representative Testifies Before Congress Against Federal GMO Labeling Bill
December 15, 2014| Blog| Viewpoint
FTC Centennial: How Health Care Antitrust Has Evolved
December 15, 2014| Blog| Viewpoint
On the Fifth Day of Privacy, California (and Delaware) gave to me
December 15, 2014| Blog| Viewpoint
Hello Newman! (and Chiasson): Second Circuit Decision Raises the Bar for Government to Prove Liability of “Remote Tippees” in Insider Trading Cases
December 15, 2014| Advisory| Viewpoint
Massachusetts Becomes the Latest Jurisdiction to Require Paid Sick Leave
December 12, 2014| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|